Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184309 | 1.00 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL2184140 | 0.85 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL2184135 | 0.85 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL12506778 | 0.84 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL2183725 | 0.84 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL2183730 | 0.84 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL14077055 | 0.82 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL2185082 | 0.82 | MAPT (0.52) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL2185072 | 0.82 | MAPT (0.52) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL2184275 | 0.78 | RAB9A (0.52) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064194-B1 | N-HYDROXYAMIDINOHETEROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE HOLDINGS CORP (US) | 2018-11-07 | — | — | EP | claimed |
| US-8507541-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-08-13 | — | — | US | claimed |
| US-20110165188-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation a Delaware corporation | 2011-07-07 | — | — | US | claimed |
| EP-2064194-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2009-06-03 | — | — | EP | claimed |
| US-20080214546-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-09-04 | — | — | US | claimed |
| WO-2008036653-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
| EP-2064194-B1 | N-HYDROXYAMIDINOHETEROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE HOLDINGS CORP (US) | 2018-11-07 | — | — | EP | disclosed |
| US-8507541-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110165188-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation a Delaware corporation | 2011-07-07 | — | — | US | disclosed |
| US-20080214546-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214546-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | MEN1 2391/4885KMT2A 675/4885SMN1; SMN2 3241/4885 |
| US-20110165188-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | MEN1 2391/4885KMT2A 675/4885SMN1; SMN2 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.